Redeye leaves a comment following Alzinova’s announcement of the preliminary outcome of its SEK50.
Redeye leaves a comment following Alzinova’s announcement of a SEK50.
Redeye leaves a comment following Alzinova’s announcement of entering a Memorandum of Understanding (MoU) with a leading Saudi healthcare pr...
Redeye provides a research update following the Q3 report published by Alzinova earlier today.
Redeye leaves a comment following Alzinova’s announcement of a SEK11m short-term loan aimed at securing near-term liquidity and operational ...
Redeye leaves a comment following Alzinova’s announcement that the FDA has granted Fast Track Designation (FTD) for its lead candidate ALZ-1...
Redeye comments on Alzinova’s announcement that the FDA has approved its IND application for ALZ-101.
Alzinova is a Sweden-based clinical-stage biopharmaceutical company seeking to advance treatments for Alzheimer’s disease (AD) via protein m...
Redeye provides a research update following the Q2 report published by Alzinova earlier today.
Redeye comments on Alzinova’s announcement of having submitted an IND application and a Fast Track Designation request to the FDA for ALZ-10...
Redeye comments on Alzinova’s recent announcements of a strategic collaboration with Worldwide Clinical Trials and promising new CSF data.
Redeye provides a research update following the Q1 report published by Alzinova earlier today.
Redeye provides a brief comment following Alzinova’s announcement of the outcome of its SEK35.
Redeye provides a short research update following Alzinova’s recent rights issue of approximately SEK35.
Redeye leaves a comment following today’s announcement of a rights issue of approximately SEK35.
Redeye leaves a comment following Alzinova’s announcement of final study results from the phase Ib study with its vaccine candidate ALZ-101.
Redeye provides a research update following the Q4 report published by Alzinova earlier today.
Redeye leaves a comment following Alzinova’s announced study data form the high-dose phase Ib extension study (part A2) with its vaccine can...
Redeye leaves a comment following Alzinova’s announced study results form the phase Ib extension study (part B) with its vaccine candidate A...
Redeye leaves a comment following Alzinova’s announcement of the appointment of Tord Labuda as the new CEO of the company.
Redeye leaves a note following Alzinova’s announcement of Carol Routledge having been appointed as the new acting CEO of the company.
Redeye leaves a comment following today’s announcement of the outcome of Alzinova’s recent rights issue.
Redeye leaves a short comment on the exclusive option and license agreement between AC Immune and Takeda for the Alzheimer’s disease vaccine...
Redeye leaves a comment following today’s announcement of a rights issue of approximately SEK34.
Redeye leaves a comment following today’s announcement that Kristina Torfgård has decided to leave her role as CEO of Alzinova.
Redeye leaves a comment following Alzinova’s announcement of updated in-depth analysis of data from part A of Alzinova's phase 1b study with...
Redeye leaves a comment on the Q4 report published by Alzinova earlier today.
Redeye leaves a short comment following Alzinova’s announcement of a received approval from regulatory authorities to evaluate a higher dose...
Redeye leaves a comment following Alzinova’s announcement of a completed primary analysis of the phase Ib study with its vaccine candidate A...
Redeye provides a short research update following the positive phase Ib results with lead candidate ALZ-101 published by Alzinova last week.
Redeye is encouraged to learn that Alzinova’s lead candidate, ALZ-101, met the primary endpoint of safety and tolerability in its phase Ib t...
Alzinova meddelade idag positiva topline-resultat från den kliniska fas Ib-studiens A-del med vaccinkandidaten ALZ-101.
Det lilla bolaget på en stor marknad Alzinova är ett svenskt biofarmabolag i klinisk fas som utvecklar ett terapeutiskt vaccin och en monok...
Redeye provides a research update in regards to the Q3 report published by Alzinova earlier today.
Redeye leaves a comment on the Q2 report published by Alzinova earlier today.
Redeye leaves a note following Alzinova's update regarding its Pre-IND meeting with the FDA.
Redeye leaves a comment on the Q1 report published by Alzinova earlier today.
Redeye comments on the new positive data from the second interim analysis of the ongoing phase Ib study with Alzinova’s vaccine candidate AL...
Redeye provides a comment on Alzinova’s TO3 exercise outcome, which generated SEK26.
För Alzinova stundar en spännande period då ny interimdata från Alzheimer-projektet ALZ-101 ska läsas av i vår.
Redeye provides a research update on Alzinova following the company’s Q4 report published earlier today and recent clinical progress with le...
Redeye leaves a short comment following Alzinova’s announcement earlier today.
Redeye comments on the new positive safety review and interim data from the ongoing phase Ib study with vaccine candidate ALZ-101.
Redeye leaves a comment on the Q3 report published by Alzinova earlier today.
Efter positiva studier från Eisab/Biogen med lecanemab mot Alzheimers sjukdom ser vi att caset för Alzinovas kandidat ALZ-101 stärkts väsent...
Redeye revisits the Alzinova equity story following the company’s continued pipeline progress and recent rights issue.
Alzinova, som utvecklar läkemedelskandidater för behandling av Alzheimers sjukdom, går in i en intensiv fas med sin huvudkandidat ALZ-101.
Redeye leaves a comment on the announced rights issue and Q1 report published by Alzinova earlier this morning.
Redeye provides a comment on the Q4 report published by Alzinova earlier this morning.
Mangold tar upp bevakning av Alzinova med en köprekommendation och riktkurs 13 kronor på 12 månaders sikt.
There are no big surprises in Alzinova’s Q2’21 interim report.
